



LEGISLATIVE FISCAL OFFICE
Fiscal Note

Fiscal Note On: **HB 423** HLS 25RS 985

Bill Text Version: **ENGROSSED**

Opp. Chamb. Action: **W/ SEN FLOOR AMD**

Proposed Amd.:

Sub. Bill For.:

Date: June 10, 2025	9:35 AM	Author: LACOMBE
Dept./Agy.: Louisiana Department of Health		
Subject: Provides relative to healthcare providers displaying evidence		Analyst: Luis Galvan

HEALTH CARE/PROVIDERS

EGF NO IMPACT See Note

Page 1 of 1

Provides relative to healthcare providers displaying evidence of proper licensure in advertising

Proposed law amends R.S. 22:1060.7(B)(3) to prohibit health insurers from substituting a prescribed opioid medication that has defined abuse-deterrent properties with an immediate or extended release alternative that does not have such properties, when the prescription is deemed medically necessary by a licensed physician. Proposed law also amends R.S. 51:413(B) to clarify that violations related to the use of the title “Doctor” or “Dr.” in advertising are enforceable under the Louisiana Unfair Trade Practices and Consumer Protection Law and any rules promulgated by the appropriate professional licensing board.

EXPENDITURES	2025-26	2026-27	2027-28	2028-29	2029-30	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

REVENUES	2025-26	2026-27	2027-28	2028-29	2029-30	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

EXPENDITURE EXPLANATION

There is no anticipated direct material effect on governmental expenditures as a result of this measure. The proposed restrictions on substituting opioid prescriptions apply to private health insurers and do not impose responsibilities or costs on state agencies. Additionally, enforcement of advertising violations related to the use of the title “Doctor” or “Dr.” will remain under the authority of professional licensing boards. These boards are expected to carry out enforcement using existing administrative processes and resources, and do not anticipate the need for additional staff or funding.

REVENUE EXPLANATION

There is no anticipated direct material effect on governmental revenues as a result of this measure. Proposed law does not impose new licensure fees, fines, penalties, or create any new revenue-generating mechanisms. The provisions regarding opioid prescription substitutions apply to private health insurers, and enforcement of advertising violations remains within existing frameworks overseen by professional licensing boards.

Senate

Dual Referral Rules

House

☐ 13.5.1 >= \$100,000 Annual Fiscal Cost {S & H}

☐ 6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}

☐ 13.5.2 >= \$500,000 Annual Tax or Fee Change {S & H}

☐ 6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}

Patrice Thomas
Deputy Fiscal Officer